CVS Health Surges with Dividend Boost and Strong 2024 Revenue Forecast

208

CVS Health (CVS) witnessed a surge in its shares on Tuesday following an announcement of an increased quarterly dividend and optimistic projections for 2024 sales. The healthcare and drugstore giant is strategically streamlining its operations, aligning with ongoing discussions of consolidation in the health insurance sector.

For the upcoming year, CVS anticipates total revenue to reach at least $366 billion, surpassing the forecast by LSEG, which hovers around $346 billion. The adjusted profit is projected to be approximately $8.51 per share. The company reiterated its 2023 forecasts, expecting adjusted profit in the range of $8.50 to $8.70 per share, with cash flows from the overall business falling between $12.5 billion to $13.5 billion.

Additionally, CVS has increased its quarterly dividend by 10%, reaching 66.5 cents per share, payable on Feb. 1 to shareholders of record as of Jan. 22.

CEO Karen Lynch expressed confidence in the company’s strategy, stating, “We are successfully executing on our strategy to advance the future of health care while unlocking new value for consumers.” Lynch highlighted the combination of businesses and strategic growth areas as key drivers to lower the total cost of care, enhance health outcomes, and fulfill commitments to customers, consumers, and shareholders.

In a bid to enhance its integrated healthcare services, CVS has decided to rebrand its Health Services segment as CVS Healthspire. This segment will encompass various units, including Oak Street Health, Signify, and MinuteClinic.

Mike Pykosz, interim president of Oak Street Health, emphasized the benefits of delivering care in a more integrated manner, particularly for patients with chronic health conditions, improving both health outcomes and the patient experience.

The move comes amid reports of CVS rivals Cigna (CI) and Humana (HUM) engaging in early-stage merger talks. If successful, this merger could create one of the largest health insurers, challenging the dominance of UnitedHealth (UNH). However, potential hurdles may arise, particularly with the Federal Trade Commission (FTC) taking an active stance against megamergers under the leadership of Lina Khan. The FTC has cautioned major pharmacy-benefit managers, including CVS’s Caremark, about anticipated changes in industry regulation.